ClearPoint Neuro, Inc. CLPT
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About CLPT
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
ClearPoint Neuro, Inc. is a U.S.-based medical technology company focused on developing and commercializing platform technologies for minimally invasive neurosurgery and precision drug delivery to the brain. The company operates within the neurosurgical navigation, neurointervention, and gene and cell therapy enablement industries. Its core offerings are designed to support MRI-guided procedures in the brain and spine, particularly for applications involving deep brain stimulation, laser ablation, biopsies, and the direct delivery of biologics such as gene therapies. The company generates revenue primarily through capital equipment sales, disposable surgical products, software platforms, service agreements, and collaborations with pharmaceutical and biotechnology companies.
The company’s principal business lines center around the ClearPoint Neuro Navigation System, related disposable devices, and therapy-enabling services for partners developing central nervous system treatments. ClearPoint Neuro serves hospitals, academic medical centers, neurosurgeons, and life sciences companies pursuing therapies for neurological disorders. The company has positioned itself as a specialized provider in MRI-guided neurosurgical intervention and intracranial drug delivery, an area with relatively few established competitors due to technical complexity, regulatory requirements, and the need for integration with advanced imaging environments. Originally founded as MRI Interventions, Inc., the company later rebranded to ClearPoint Neuro to reflect broader ambitions in precision neurosurgery and biologic delivery technologies.
Business Operations
ClearPoint Neuro conducts operations through integrated medical device and therapy partnership activities. Its primary commercial platform is the ClearPoint System, which enables real-time MRI-guided surgical navigation and targeting for minimally invasive neurosurgical procedures. The company derives recurring revenue from disposable components used in procedures, software and hardware installations, service contracts, and collaborative development arrangements with biotechnology and pharmaceutical firms. The company’s technologies are used in procedures involving laser interstitial thermal therapy, deep brain stimulation lead placement, ventricular access, and biologic infusion into specific brain regions.
The company operates primarily in the United States but also maintains international commercial relationships and distribution activities across parts of Europe, Asia-Pacific, and other selected markets. ClearPoint Neuro controls proprietary software, navigation hardware, and delivery cannula technologies associated with intracranial therapeutic administration. The company has established partnerships with multiple gene therapy and cell therapy developers pursuing treatments for conditions such as Parkinson’s disease, AADC deficiency, epilepsy, and other neurological disorders. Public filings and investor materials identify collaborations with biotechnology firms developing CNS-directed therapeutics, although some commercial and financial terms remain undisclosed in public documentation.
Strategic Position & Investments
ClearPoint Neuro’s strategic direction has focused on expanding the adoption of MRI-guided neurosurgery while positioning the company as an enabling infrastructure provider for emerging CNS gene and cell therapies. The company has invested in expanding its therapy development support capabilities through manufacturing, delivery optimization, procedural planning, and clinical collaboration services. Its strategy emphasizes recurring procedural revenue growth alongside long-term participation in the expanding neurotherapeutics market.
The company has also pursued growth through technology expansion and selective acquisitions. ClearPoint Neuro acquired CLP Neurosteer, Inc. assets related to neuro-navigation technologies and has invested in enhancing compatibility between its systems and biologic delivery workflows. The company has increasingly emphasized partnerships tied to gene therapy clinical programs, including support for direct brain infusion procedures requiring precision targeting. Public company disclosures indicate that management views neurodegenerative disease treatment delivery, MRI-guided intervention, and biologic administration as central long-term growth sectors.
Geographic Footprint
ClearPoint Neuro is headquartered in Solana Beach, California, with operational and commercial activities centered primarily in the United States. The company’s products are installed at hospitals and research institutions performing advanced neurosurgical procedures, particularly at academic and specialty neurological centers. The U.S. remains the company’s dominant revenue market according to public filings.
Internationally, the company maintains commercial reach through distributors, partnerships, and collaborative clinical programs across regions including Europe, Canada, and parts of Asia-Pacific. Its technologies have been utilized in multinational clinical studies involving gene and cell therapy delivery to the central nervous system. While international revenue remains smaller relative to domestic operations, the company’s strategic collaborations with global biotechnology developers provide broader operational influence beyond direct sales infrastructure.
Leadership & Governance
ClearPoint Neuro is led by an executive team with backgrounds in medical devices, neurosurgery technologies, and life sciences commercialization. Management has consistently emphasized precision medicine, minimally invasive intervention, and enabling next-generation neurological therapies as core strategic priorities. Corporate governance is overseen by a board of directors with experience in healthcare technology, medical devices, and biotechnology.
Key executives include:
- Joseph Burnett – President and Chief Executive Officer
- Daniel R. Levangie – Chief Financial Officer
- Stacie H. Magnan – President, Biologics and Drug Delivery
- Matthew V. Likens – Chairman of the Board
- Jeremy C. Stigall – Chief Business Officer
Information presented above is based on publicly available disclosures including SEC filings, investor presentations, company reports, and major financial and healthcare industry publications. Certain partnership details and financial terms remain limited to publicly disclosed information.